Biosimilars in rheumatology: Pharmacological and pharmacoeconomic issues

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Lapadula, G ^a   Ferraccioli, G F ^b  

^a UNIVERSITY OF BARI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bioequivalence; Biosimilar; Immunogenicity; Interchangeability

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; BIOEQUIVALENCE; CHRONIC PAIN; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISTRESS SYNDROME; FATIGUE; HEALTH CARE COST; JOINT MOBILITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 84870284603     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. FLEISCHMANN R, WELLS AF, KAVANAUGH A: New biologic agents in patients with rheumatoid arthritis. Update to Rheum Dis Clin NA 2011;4:3-20.
2. van den HOUT WB: The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010;69(Suppl. 1):i89-i91.
3. FILIPOVIC I, WALKER D, FORSTER F, CURRY AS: Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1083-90.
4. KIRCHHOFF T, RUOF J, MITTENDORF T et al.: Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings. Rheumatology (Oxford) 2011;50:756-61.
5. BARRETT EM, SCOTT DG, WILES NJ, SYMMONS DP: The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 2000;39:1403-9.
6. KOBELT G, JONSSON L, YOUNG A, EBERHARDT K: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35.
7. RANTALAIHO VM, KAUTIAINEN H, JARVENPAA S et al.: Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8. Ann Rheum Dis 2012 Jun. 7. [Epub ahead of print]
8. SCHOELS M, WONG J, SCOTT DL et al.: Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
9. BOONEN A, PATEL V, TRAINA S, CHIOU CF, MAETZEL A, TSUJI W: Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008;35:662-7.
10. HARRISON MJ: Challenges in assessing costs of rheumatoid arthritis. Case Manager 2003;14:65-72.
11. CHEN YF, JOBANPUTRA P, BARTON P et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-xiii, 1.
12. TANNO M, NAKAMURA I, ITO K et al.: Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84.
13. DOAN QV, CHIOU CF, DUBOIS RW: Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555-69.
14. BRENNAN A, BANSBACK N, NIXON R et al.: Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologies Registry. Rheumatology (Oxford) 2007;46:1345-54.
15. REICHERT JM, BECK A: Biosimilar monoclonal antibodies. mAbs 1:5, 394-416; September/October 2009; © 2009 Landes Bioscience.
16. COFEPRIs: http://www.cofepris.gob.mx/AZ/Paginas/Farmacovigilancia/ Comunicados.aspx-04/04/2012
17. REICHERT J: Next generation and biosimilar monoclonal antibodies. mAbs 3:3, 223-240; May/June 2011; © 2011 Landes Bioscience.
18. FOOD and DRUG ADMINISTRATION: Scientific considerations in demonstrating biosimilarity to a reference product: draft guidance February 2012. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed April 4.2012.
19. FOOD AND DRUG ADMINISTRATION: Quality considerations in demonstrating biosimilarity to a reference product: draft guidance February 2012. Available from URL: http://www.fda.gov/downloads/Drugs/Guidance- ComplianceRegulatorylnformation/Guidances/UCM291134.pdf. Accessed April 4.2012.
20. AHMED I, KASPAR B, SHARMA U: Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012;34:400-19.